B-lymphoblastic leukaemia/lymphoma (B-ALL/LBL) is diagnosed by a combination of morphology and immunophenotyping, whereas further classification is now largely by defined cytogenetic and/or molecular abnormalities. These genetic types form the basis of the present classification, and they may be associated with characteristic morphological, immunophenotypic, or clinical features with prognostic and/or therapeutic implications.
- Bone Marrow: Transfer 3 mL bone marrow to a Green (Sodium Heparin). (Min: 1 mL)
- Whole Blood: Transport 5 mL whole blood. (Min: 2 mL)
- Sample collection: Non-diluted bone marrow aspirate. Collect in a sodium heparinized Vacutainer.
- Specimen preparation: Do not freeze or expose to extreme temperatures.
- Storage/Transport Temperature: Room temperature.
- Unacceptable Conditions: Frozen specimens. Clotted specimens.
- Remarks:
- Stability: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Fluorescence in situ Hybridization (FISH)
Sample received to report Turnaround time (TAT)
3 working days
————-
Interpretive Data
Probes included: BCR-ABL1, TCF3/PBX1, MYC, KMT2A(MLL), IGH, TP53 The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluation.
Resources
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report